Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:
• Individuals with \< 34 0/7 weeks of gestation.
• Individuals with severe preeclampsia or HELLP features.
Locations
United States
Minnesota
Mayo Clinic Minnesota
RECRUITING
Rochester
Contact Information
Primary
Gonzalez Suarez
507-284-2511
Time Frame
Start Date: 2025-04-01
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 14
Treatments
Experimental: Revulizumab Treatment
Subjects will receive an single-dose infusion of Ravulizumab.
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic